Press Releases Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Real-time Estimate Cboe BZX Other stock markets 01:17:18 14/05/2024 am IST			5-day change	1st Jan Change
0.315 ^USD	+1.45%		+2.19%	+1.20%

30/04	Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	CI
30/04	XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024	07/05	AQ
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network	02/05	AQ
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts	30/04	AQ
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	23/04	AQ
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	11/04	AQ
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	28/03	AQ
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	21/03	AQ
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	22/02	AQ
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	31/01	AQ
Daré Bioscience Announces Executive Team and Board of Directors Changes	27/01	AQ
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development	17/01	AQ
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases	04/01	AQ
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure	26/12	AQ
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study	20/12	AQ
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study	13/12	AQ
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause	07/12	AQ
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	04/12	AQ
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs	20/11	AQ
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting	13/11	AQ
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update	09/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Press Releases

Filters